|Awarded On||November 19, 2014|
|Title||Immunotherapy targeting triple negative breast cancer using NY-ESO-1-specific TCRs and blockade of immune suppression|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Rongfu Wang|
Breast cancer is a leading cause of cancer-related deaths of women in the United States and worldwide. Harnessing the immune system to eradicate malignant cells is a promising approach to cancer therapy. Recent FDA approval of sipuleucel-T (Provenge) for the treatment of metastatic prostate cancer and ipilimumab (Yervoy) for the treatment of melanoma represents milestones in the field of cancer immunotherapy.
Despite rapid progress of cancer immunotherapy, there is no effective therapy for patients with metastatic triple-negative breast cancer (ER/PR/HER-2-negative, TNBC). We found that NY-ESO-1 is highly expressed in 18-30 % of TNBC samples, thus serving a potential target for immunotherapy...